Claims for Patent: 5,276,137

Summary for Patent: 5,276,137

Title:	Analgesic peptides with a trifluoronorvaline modification
Abstract:	The present invention relates to analgesic enkephalin derivatives represented by the following formula: and the acid salts thereof, wherein Tyr is L-tyrosine, A.sub.1 or A.sub.2 is a glycine, and that which is not a glycine is an optically active trifluoro amino acid of the formula: ##STR1## wherein n is an integer from 1-3 and m is 1 or 2; A.sub.3 is L-Phenylalanine, or N-methyl-(L)-phenylalanine, and A.sub.4 is L-Methionine, L-Met-OH, L-Met-ol or L-Met-NH.sub.2.
Inventor(s):	Ojima; Iwao (Stony Brook, NY), Nakahashi; Kazuaki (Takaoka, JP)
Assignee:	The Research Foundation of State University of New York (New York, NY)
Application Number:	07/630,163
Patent Claims:	1. A compound of the formula Tyr-A.sub.1 -A.sub.2 A.sub.3 A.sub.4 SEQ ID NO:5 and the acid addition salts thereof, in which Tyr is L-Tyrosine; at least one of A.sub.1 or A.sub.2 is a glycine and that which is not a glycine is an optically active compound of the formula: ##STR13## wherein n is 2 or 3 A.sub.3 is L-Phenylalanine, or N-methyl-(L)phenylalanine; and A.sub.4 is L-Methionine, L-Met-ol or L-Met-NH.sub.2. 2. The compound of claim 1 wherein the acid of the acid addition salt is selected from the group consisting of organic and inorganic acids. 3. The compound of claim 2 wherein the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, citric acid, lactic acid, oxalic acid, maleic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, salicylic acid and ascorbic acid. 4. The compound of claim 2 wherein the acid is trifluoroacetic acid. 5. A compound according to claim 1, selected from the group consisting of: 6. The compound of claim 1 wherein A.sub.1 is glycine, n is 2 and A.sub.2 is (L)-TFNV, A.sub.3 is Phe and A.sub.4 is Met-NH.sub.2. 7. The compound of claim 1 wherein n is 2 and A.sub.1 is (L)-TFNV, A.sub.2 is Glycine, A.sub.3 is Phe and A.sub.4 is Met. 8. The compound of claim 1 wherein n is 2 and A.sub.1 is (L)-TFNV, A.sub.2 is Glycine, A.sub.3 is Phe and A.sub.4 is Met-NH.sub.2. 9. The compound of claim 1 wherein n is 2 and A.sub.1 is (D)-TFNV, A.sub.2 is Glycine, A.sub.3 is Phe and A.sub.4 is Met-NH.sub.2. 10. The compound of claim 1 wherein A.sub.1 is Glycine, n is 2 and A.sub.2 is (D)-TFNV, A.sub.3 is Phe and A.sub.4 is Met-NH.sub.2. 11. The compound of claim 1 wherein A.sub.1 is Glycine, n is 2 and A.sub.2 is (L) TFNV, A.sub.3 is Phe and A.sub.4 is Met-NH.sub.2. 12. The compound of claim 1 in combination with a pharmaceutically acceptable carrier. 13. The compound of claim 12 wherein the pharmaceutically acceptable carrier is selected from the group consisting of dextrose solutions, sodium chloride solutions (saline), sterile water and buffer solutions. 14. A method of treating pain which comprises providing an analgesically effective dose to a recipient of at least one compound of the formula Tyr-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 SEQ ID NO:5 and the acid addition salts thereof, in which Tyr is L-Tyrosine; at least one of A.sub.1 or A.sub.2 is a glycine and that which is not a glycine is an optically active compound of the formula: ##STR14## wherein n is 2 or 3; A.sub.3 is L-Phenylalanine, or N-methyl-(L)-phenylalanine; and A.sub.4 is L-Methionine, L-Met-ol or L-Met-NH.sub.2. 15. The method of claim 12 wherein the compound is selected from the group consisting of 16. The method of claim 15 wherein the compound is provided in combination with a pharmaceutically acceptable carrier. 17. The method of claim 15 wherein the pharmaceutically acceptable carrier is selected from the group consisting of dextrose solutions, sodium chloride solutions (saline), sterile water and buffer solutions. 18. The method of claim 15 wherein the compound is provided intramuscularly, subcutaneously or orally. 19. The method of claim 15 wherein the dosage is provided intramuscularly and the dosage ranges from about 4 .mu.g to about 17 .mu.g per kilogram bodyweight of the recipient. 20. The method of claim 18 wherein the dosage is provided intramuscularly and ranges from about 8 .mu.g to about 17 .mu.g per kilogram bodyweight of the recipient. 21. The method of claim 18 wherein the dosage is provided subcutaneously and ranges from about 7 .mu.g to about 14 .mu.g per kilogram bodyweight of the recipient. 22. The method of claim 18 wherein the dosage is provided subcutaneously and ranges from about 8 .mu.g to about 17 .mu.g per kilogram bodyweight of the recipient. 23. The method of claim 18 wherein the compound is provided orally and the dose ranges from about 20 ng to about 50 ng per kilogram bodyweight of the recipient. 24. The method of claim 18 wherein the compound is provided orally and the dose ranges from about 15 ng to about 45 ng per kilogram bodyweight of the recipient.

Details for Patent 5,276,137

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2011-01-04